Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan
Source: Cell & Gene
![23_12_CGPodcast_1280x720_Ep72 23_12_CGPodcast_1280x720_Ep72](https://vertassets.blob.core.windows.net/image/15d5216e/15d5216e-305c-4548-8aea-5961058a5570/375_250-23_12_cgpodcast_1280x720_ep72.jpg)
Orca Bio's CMO, Dr. Scott McClellan, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss how and why toxicities continue to stymie allogeneic cell therapies. They cover Orca Bio's plan to potentially lowering the risk of GvHD as well as Orca-T, the investigational high-precision allogeneic cell therapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies.
access the Podcast!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
This website uses cookies to ensure you get the best experience on our website. Learn more